Ventilator-associated Pneumonia
On this page
Direct answer
Ventilator-associated pneumonia (VAP) is pneumonia arising more than 48 hours after endotracheal intubation, produced chiefly by microaspiration of contaminated oropharyngeal secretions around the cuff and by biofilm within the tube. Diagnosis rests on a new or progressive infiltrate with fever, purulent secretions and deteriorating oxygenation, ideally with quantitative cultures. Treatment mirrors late-onset HAP with antipseudomonal and MRSA cover per the local antibiogram, and prevention rests on a bundle of head elevation, sedation minimisation and early extubation.
What you must remember
- Definition: new pneumonia developing more than 48 hours after intubation; incidence rises with the duration of ventilation, which is why shortening it is the strongest preventive act.
- Pathogenesis: oropharyngeal colonisation by enterobacteria and Pseudomonas with pooling and leakage of contaminated secretions around the cuff, biofilm within the tube, and gastric alkalinisation from acid-suppressors.
- Diagnostic standard: a new or progressive radiographic infiltrate plus at least two of fever, purulent secretions, leucocytosis or leucopenia, and worsening oxygenation; quantitative bronchoalveolar lavage growth above 10 to the power 4 colony-forming units per mL (or protected specimen brush above 10 to the power 3) supports VAP, and a clinical pulmonary infection score above six is used in many units.
- Microbiology: Pseudomonas aeruginosa, Acinetobacter baumannii and extended-spectrum beta-lactamase enterobacteria dominate in Indian units, with Staphylococcus aureus (including MRSA) after head trauma, coma and influenza.
- Empiric therapy: an antipseudomonal beta-lactam — piperacillin-tazobactam, cefepime or a carbapenem — plus a second agent (aminoglycoside or antipseudomonal fluoroquinolone) in septic shock or high-resistance settings, with linezolid or vancomycin added when MRSA risk exists; inhaled colistin may supplement intravenous therapy for extensively resistant gram-negatives per local policy.
- De-escalate on culture results and treat about seven days in responders, with eight days or longer considered for non-fermenting organisms in selected patients.
- Prevention bundle: head-end elevation of 30 to 45 degrees, daily sedation interruption with extubation-readiness trials, oral hygiene, subglottic secretion drainage when ventilation beyond 48 to 72 hours is expected, early mobilisation and cautious stress-ulcer prophylaxis.
Day five of ventilation, secretions turning purulent
A polytrauma patient, intubated since admission, spikes a fever on day five; secretions are purulent, the white count has risen, oxygenation has drifted up and the radiograph shows a new left lower-zone infiltrate. Pneumonia more than 48 hours after intubation is ventilator-associated by definition, and the mechanism is already in view — oropharyngeal colonisation leaking around the cuff, biofilm within the tube, a stomach alkalinised by the acid-suppressor. Before antibiotics, culture: endotracheal aspirate or bronchoalveolar lavage, where quantitative growth above 10 to the power 4 colony-forming units per mL (protected specimen brush above 10 to the power 3) supports the diagnosis. Then treat like late-onset HAP per the local antibiogram — an antipseudomonal beta-lactam, plus a second agent in septic shock or high-resistance settings, plus linezolid or vancomycin for MRSA risk, which his head trauma raises; Watch the trajectory: de-escalate when susceptibilities return, treat about seven days in responders, and resist changing antibiotics each time an aspirate grows something new. Meanwhile re-anchor prevention — head end at 30 to 45 degrees, daily sedation interruption with extubation-readiness trials, oral hygiene, subglottic secretion drainage, and stopping the proton-pump inhibitor he never needed.
Where students slip
Overdiagnosis is the headline error: tracheobronchitis and colonisation get labelled VAP, when the difference lies in systemic signs, a genuinely new infiltrate and rising oxygen requirements — culture alone never diagnoses it, and the aspirate of every long-ventilated patient grows something. The second slip is partial prevention: head elevation alone is not the bundle, and the discriminators are subglottic suction drainage and daily sedation interruption with extubation readiness. The third is the stress-ulcer nuance: routine acid suppression promotes colonisation, so prophylaxis is reserved for patients with a real indication. The number set — 48 hours, 10 to the power 4 and 10 to the power 3 colony-forming units, seven days — plus Acinetobacter and Pseudomonas as the Indian unit organisms, carries the rest.
Frequently asked questions
When does pneumonia in a ventilated patient qualify as VAP?
When it develops more than 48 hours after endotracheal intubation.
How is VAP diagnosed?
A new or progressive infiltrate with fever, purulent secretions, altered white cell count and worsening oxygenation, with quantitative culture support.
Which organisms cause most VAP in Indian ICUs?
Multidrug-resistant non-fermenters, chiefly Acinetobacter baumannii and Pseudomonas aeruginosa, besides resistant enterobacteria and Staphylococcus aureus.
What are the core preventive measures?
Head-end elevation of 30 to 45 degrees, daily sedation holds with extubation readiness trials, oral hygiene, subglottic secretion drainage and minimising the duration of intubation.
How long is VAP treated?
Usually seven days in clinically responding patients, individualised for non-fermenting gram-negative organisms and poorly resolving disease.
Why is routine stress-ulcer prophylaxis discouraged?
Gastric acid suppression promotes oropharyngeal and gastric colonisation with resistant organisms, raising VAP risk in patients without a strong indication.